New Data and Clinical Perspectives on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States. An estimated 191,930 new cases are diagnosed annually, and 33,330 people die from the disease (ACS, 2020). Most patients with metastatic hormone-sensitive prostate cancer (HSPC) present with relapse after local treatment, while approximately 5% of all prostate cancer patients present with de novo metastatic HSPC (Ng et al, 2020). The five-year overall survival rate for metastatic HSPC remains only 29.8% (Hahn et al, 2018). The treatment of metastatic HSPC has expanded dramatically in recent years with the introduction of several novel therapies. With an array of treatments available, including androgen deprivation therapy (ADT), chemotherapy, and second-generation antiandrogens such as abiraterone, enzalutamide, and apalutamide, clinicians face the challenge of determining the optimal sequencing of therapies for individual patients, with limited data to guide treatment choices (Ng et al, 2020).

TARGET AUDIENCE

Oncologists, urologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with hormone-sensitive prostate cancer (HSPC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Discuss patient and tumor characteristics that can inform tailored therapeutic approaches for patients with metastatic HSPC
2.) Evaluate emerging data on novel treatment combinations and sequences for patients with metastatic HSPC
3.) Assess strategies to optimize the safety and tolerability of novel therapies for metastatic HSPC